[Evaluation of the performance of immunological parameters as indicators for clinical progression of chronic HTLV-1 infection].
This study evaluated the performance of single and combined laboratory parameters, B-lymphocyte percentages (%LB), T/B cell ratio and %CD8+HLA-DR+/CD8+, to differentiate asymptomatic cases (AS) from HAM/TSP patients (HT) within a population of HTLV-1 seropositive cases. Percentage indices demonstrated that each parameter alone presented moderate performance, with co-negativity of 83 and 91% for %LB and T/B cell ratio, respectively, and co-positivity of 78% for %CD8+HLA-DR+/CD8+. Combined analysis (%CD8+HLA-DR+/CD8+ and T/B cell ratio) did not show any substantial performance enhancement (co-positivity = 75% and co-negativity = 74%). Likelihood ratio analysis using different value ranges for the separate parameters revealed that HTLV-1 seropositive cases with %LB<7%, T/B cell ratio>11 and %CD8+HLA-DR+/CD8+>70% would have, respectively, 11, 19 and 10 times greater chance of belonging to the HT group. Therefore, use of these phenotypic indicators as complementary laboratory methods for monitoring the clinical progression of chronic HTLV-1 infection is recommended.
Coelho-dos-Reis
Jordana Grazziela Alves
JG
Centro de Pesquisas René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, MG.
Rocha
Roberta Dias Rodrigues
RD
Brito-Melo
Gustavo Eustáquio Alvim
GE
Ribas
João Gabriel
JG
Carneiro-Proietti
Anna Bárbara de Freitas
AB
Catalan-Soares
Bernadete
B
Barbosa-Stancioli
Edel Figueiredo
EF
Martins-Filho
Olindo Assis
OA
D001402:B-Lymphocytes / Q000276:immunology*; D015415:Biomarkers; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002908:Chronic Disease; D018450:Disease Progression; D006684:HLA-DR Antigens / Q000276:immunology*; D015490:HTLV-I Infections / Q000097:blood / Q000276:immunology*; D006801:Humans; D018655:Lymphocyte Count; D015493:Paraparesis, Tropical Spastic / Q000097:blood / Q000276:immunology; D010641:Phenotype; D011237:Predictive Value of Tests; D012372:ROC Curve; D015203:Reproducibility of Results
D015415:Biomarkers; D006684:HLA-DR Antigens